FRANKLIN BIOTECHNOLOGY DISCOVERY FUND
Fund
FRBRX
Price as of:
$146.01
+ $0.09
+ 0.06%
Primary Theme
fund company
Name
As of 11/21/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
8.1%
1 yr return
32.3%
3 Yr Avg Return
3.8%
5 Yr Avg Return
5.3%
Net Assets
$897 M
Holdings in Top 10
43.7%
52 WEEK LOW AND HIGH
$145.9
N/A
N/A
Expenses
OPERATING FEES
Expense Ratio 0.77%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 47.30%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$1,000,000
IRA
N/A
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 11/21/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
FRBRX - Profile
Distributions
- YTD Total Return 8.1%
- 3 Yr Annualized Total Return 3.8%
- 5 Yr Annualized Total Return 5.3%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.25%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameFRANKLIN BIOTECHNOLOGY DISCOVERY FUND
-
Fund Family NameFranklin Templeton Investments
-
Inception DateSep 13, 2013
-
Shares Outstanding84661
-
Share ClassR6
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerEvan McCulloch
FRBRX - Performance
Return Ranking - Trailing
| Period | FRBRX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 8.1% | -27.4% | 19.9% | 35.85% |
| 1 Yr | 32.3% | -13.7% | 48.1% | 6.29% |
| 3 Yr | 3.8%* | -28.0% | 9.5% | 23.68% |
| 5 Yr | 5.3%* | -7.8% | 12.2% | 75.34% |
| 10 Yr | 4.3%* | 0.2% | 13.1% | 81.98% |
* Annualized
Return Ranking - Calendar
| Period | FRBRX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 18.9% | -12.6% | 19.0% | 1.26% |
| 2022 | -12.7% | -53.9% | 3.2% | 50.66% |
| 2021 | -27.7% | -39.6% | 24.2% | 96.05% |
| 2020 | 14.7% | -13.6% | 178.2% | 42.95% |
| 2019 | 24.2% | 3.8% | 63.8% | 29.32% |
Total Return Ranking - Trailing
| Period | FRBRX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 8.1% | -27.4% | 19.9% | 35.85% |
| 1 Yr | 32.3% | -13.7% | 48.1% | 6.29% |
| 3 Yr | 3.8%* | -28.0% | 9.5% | 23.68% |
| 5 Yr | 5.3%* | -7.8% | 12.2% | 75.34% |
| 10 Yr | 4.3%* | 0.2% | 13.1% | 81.98% |
* Annualized
Total Return Ranking - Calendar
| Period | FRBRX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 18.9% | -12.6% | 19.0% | 1.89% |
| 2022 | -12.3% | -53.9% | 3.7% | 63.16% |
| 2021 | -17.4% | -33.9% | 26.0% | 94.08% |
| 2020 | 30.3% | -0.7% | 180.6% | 29.53% |
| 2019 | 35.3% | 4.6% | 63.8% | 8.27% |
NAV & Total Return History
FRBRX - Holdings
Concentration Analysis
| FRBRX | Category Low | Category High | FRBRX % Rank | |
|---|---|---|---|---|
| Net Assets | 897 M | 6.66 M | 45.7 B | 49.69% |
| Number of Holdings | 95 | 25 | 430 | 43.40% |
| Net Assets in Top 10 | 411 M | 2.12 M | 22.1 B | 53.46% |
| Weighting of Top 10 | 43.71% | 18.4% | 79.7% | 62.89% |
Top 10 Holdings
- Amgen, Inc. 8.19%
- Regeneron Pharmaceuticals, Inc. 7.14%
- Vertex Pharmaceuticals, Inc. 6.04%
- Insmed, Inc. 3.76%
- Ascendis Pharma A/S 3.61%
- Gilead Sciences, Inc. 3.27%
- Intra-Cellular Therapies, Inc. 2.97%
- Institutional Fiduciary Trust Money Market Portfolio 2.97%
- Biogen, Inc. 2.93%
- AstraZeneca plc 2.83%
Asset Allocation
| Weighting | Return Low | Return High | FRBRX % Rank | |
|---|---|---|---|---|
| Stocks | 98.42% | 87.34% | 106.13% | 36.48% |
| Cash | 3.57% | 0.00% | 33.01% | 32.08% |
| Bonds | 0.53% | 0.00% | 12.39% | 3.14% |
| Convertible Bonds | 0.37% | 0.00% | 0.37% | 1.30% |
| Preferred Stocks | 0.28% | 0.00% | 7.86% | 25.79% |
| Other | 0.00% | -22.99% | 23.24% | 73.58% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | FRBRX % Rank | |
|---|---|---|---|---|
| Healthcare | 99.75% | 59.26% | 100.00% | 57.79% |
| Basic Materials | 0.25% | 0.00% | 7.16% | 27.92% |
| Utilities | 0.00% | 0.00% | 0.00% | 51.95% |
| Technology | 0.00% | 0.00% | 22.69% | 55.84% |
| Real Estate | 0.00% | 0.00% | 5.89% | 54.55% |
| Industrials | 0.00% | 0.00% | 7.02% | 55.84% |
| Financial Services | 0.00% | 0.00% | 1.60% | 67.53% |
| Energy | 0.00% | 0.00% | 0.00% | 51.95% |
| Communication Services | 0.00% | 0.00% | 9.11% | 54.55% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 55.84% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 54.55% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | FRBRX % Rank | |
|---|---|---|---|---|
| US | 97.21% | 66.06% | 104.41% | 31.45% |
| Non US | 1.21% | 0.00% | 28.87% | 54.72% |
Bond Sector Breakdown
| Weighting | Return Low | Return High | FRBRX % Rank | |
|---|---|---|---|---|
| Corporate | 33.28% | 0.00% | 81.57% | 7.97% |
| Cash & Equivalents | 3.57% | 0.00% | 100.00% | 30.82% |
| Derivative | 0.00% | 0.00% | 23.24% | 66.04% |
| Securitized | 0.00% | 0.00% | 0.00% | 51.45% |
| Municipal | 0.00% | 0.00% | 0.00% | 51.45% |
| Government | 0.00% | 0.00% | 29.44% | 52.17% |
Bond Geographic Breakdown
| Weighting | Return Low | Return High | FRBRX % Rank | |
|---|---|---|---|---|
| US | 0.53% | 0.00% | 11.75% | 3.14% |
| Non US | 0.00% | 0.00% | 3.33% | 54.72% |
FRBRX - Expenses
Operational Fees
| FRBRX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.77% | 0.08% | 4.48% | 71.70% |
| Management Fee | 0.61% | 0.03% | 1.25% | 24.53% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | 0.15% | 0.03% | 0.25% | 62.16% |
Sales Fees
| FRBRX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
| FRBRX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| FRBRX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 47.30% | 0.00% | 238.00% | 47.41% |
FRBRX - Distributions
Dividend Yield Analysis
| FRBRX | Category Low | Category High | FRBRX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 6.24% | 69.81% |
Dividend Distribution Analysis
| FRBRX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annual | Annual | Monthly | Annual |
Net Income Ratio Analysis
| FRBRX | Category Low | Category High | FRBRX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.25% | -2.54% | 1.85% | 52.63% |
Capital Gain Distribution Analysis
| FRBRX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Dec 20, 2022 | $0.586 | OrdinaryDividend |
| Dec 15, 2021 | $18.283 | OrdinaryDividend |
| Dec 15, 2020 | $10.392 | CapitalGainShortTerm |
| Dec 15, 2020 | $14.451 | CapitalGainLongTerm |
| Dec 16, 2019 | $14.164 | CapitalGainLongTerm |
| Dec 17, 2018 | $2.343 | CapitalGainShortTerm |
| Dec 17, 2018 | $2.207 | CapitalGainLongTerm |
| Dec 15, 2017 | $1.088 | CapitalGainShortTerm |
| Dec 15, 2017 | $2.509 | CapitalGainLongTerm |
| Dec 15, 2016 | $4.204 | CapitalGainLongTerm |
| Dec 15, 2016 | $2.302 | OrdinaryDividend |
| Dec 15, 2015 | $3.818 | CapitalGainShortTerm |
| Dec 15, 2015 | $9.959 | CapitalGainLongTerm |
| Dec 15, 2014 | $3.728 | CapitalGainShortTerm |
| Dec 15, 2014 | $2.941 | CapitalGainLongTerm |
| Dec 16, 2013 | $1.584 | CapitalGainShortTerm |
| Dec 16, 2013 | $7.209 | CapitalGainLongTerm |
FRBRX - Fund Manager Analysis
Managers
Evan McCulloch
Start Date
Tenure
Tenure Rank
Sep 15, 1997
24.72
24.7%
Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.
Wendy Lam
Start Date
Tenure
Tenure Rank
Sep 01, 2018
3.75
3.8%
Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co. Ms. Lam has a Ph.D degree.
Akiva Felt
Start Date
Tenure
Tenure Rank
Jan 27, 2020
2.34
2.3%
Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.88 | 0.25 |